An In Vitro Diagnostic Assay to prognose survival in Chronic MyeloMonocytic Leukemia

Acobiom proposes a qRT-PCR test to prognose a 4-year survival for patients suffered from Chronic Myelomonocytic Leukemia.

Acobiom discovered and patented a new set of innovative biomarkers identified through gene expression analyses and performed on several cell lines and blood samples. These biomarkers associated to a positive 4-year survival prognosis in Chronic MyeloMonocytic Leukemia have been validated in a clinical trial lead by the Nimes hospital (France).

This clinical study has been described in a scientific publication.

An In Vitro Diagnostic Assay based on these CMML biomarkers and qRT-PCR technology has been developped and is available for « research use only ». This In Vitro Diagnostic Assay can be ordered for « research use only ».

 

If you need more information, please contact our business development department
T: +33(0)467 419 748, Email: info@acobiom.com